Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

That 30% was incorrect by MF. Take a look at this attachment for a better reference.

I believe we're much closer to 80-85% given 1 single Ph3 trial exact duplicate of Ph2 with P-Value of <.001. Fast track approval and open communication with FDA while designing Ph3 protocol to meet FDA approval guidelines. FDA basically told AUPH, do it one more time and you're good. P-Value of <.001 means there's less than 1 in 1000 chance it was a fluke...I like those odds!

I'm guessing MF keeps putting out articles on AUPH because we have so many retail eyes on us right now, and they can attract a lot of people with their click-bate on the bottom of each article.

https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf